New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome
Acquired hemophilia A and acquired von Willebrand syndrome are rare, but life-threatening bleeding disorders that require prompt diagnosis and treatment by hematologists. Acquired hemophilia A is defined as an acquired severe bleeding tendency caused by autoantibody formation against coagulation fac...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000586 |
| _version_ | 1797285659959885824 |
|---|---|
| author | Frank W. G. Leebeek |
| author_facet | Frank W. G. Leebeek |
| author_sort | Frank W. G. Leebeek |
| collection | DOAJ |
| description | Acquired hemophilia A and acquired von Willebrand syndrome are rare, but life-threatening bleeding disorders that require prompt diagnosis and treatment by hematologists. Acquired hemophilia A is defined as an acquired severe bleeding tendency caused by autoantibody formation against coagulation factor VIII. Acquired von Willebrand syndrome is characterized by a new onset bleeding tendency caused by a reduced concentration and/or function of von Willebrand factor. These disorders are associated with a variety of underlying disorders, including various hematological malignancies, for example, plasma cell disorders, lymphoproliferative disorders, monoclonal gammopathy of undetermined significance, and myeloproliferative neoplasms. It is of utmost important to recognize these acquired bleeding disorders in these patients who are at risk for severe bleeding, and to perform additional diagnostic hemostasis laboratory evaluation. This will enable immediate diagnosis of the acquired bleeding disorder and management of both the bleeding episodes and the causative underlying disorder. In recent years, several new etiological factors for acquired hemophilia A, such as treatment with immune checkpoint inhibitors or DPP-4 inhibitors and SARS-CoV2 infection, and for acquired von Willebrand syndrome, for example, left ventricular assist devices, have been identified and also new treatment options have become available. In this concise review, the most recent data on etiology, diagnosis, and treatment of acquired bleeding disorders are presented and discussed. |
| first_indexed | 2024-03-07T18:06:21Z |
| format | Article |
| id | doaj.art-45f82314e56546c78194741a5a4b6b4a |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:06:21Z |
| publishDate | 2021-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-45f82314e56546c78194741a5a4b6b4a2024-03-02T09:13:42ZengWileyHemaSphere2572-92412021-06-0156e58610.1097/HS9.0000000000000586202106000-00016New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand SyndromeFrank W. G. Leebeek0Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the NetherlandsAcquired hemophilia A and acquired von Willebrand syndrome are rare, but life-threatening bleeding disorders that require prompt diagnosis and treatment by hematologists. Acquired hemophilia A is defined as an acquired severe bleeding tendency caused by autoantibody formation against coagulation factor VIII. Acquired von Willebrand syndrome is characterized by a new onset bleeding tendency caused by a reduced concentration and/or function of von Willebrand factor. These disorders are associated with a variety of underlying disorders, including various hematological malignancies, for example, plasma cell disorders, lymphoproliferative disorders, monoclonal gammopathy of undetermined significance, and myeloproliferative neoplasms. It is of utmost important to recognize these acquired bleeding disorders in these patients who are at risk for severe bleeding, and to perform additional diagnostic hemostasis laboratory evaluation. This will enable immediate diagnosis of the acquired bleeding disorder and management of both the bleeding episodes and the causative underlying disorder. In recent years, several new etiological factors for acquired hemophilia A, such as treatment with immune checkpoint inhibitors or DPP-4 inhibitors and SARS-CoV2 infection, and for acquired von Willebrand syndrome, for example, left ventricular assist devices, have been identified and also new treatment options have become available. In this concise review, the most recent data on etiology, diagnosis, and treatment of acquired bleeding disorders are presented and discussed.http://journals.lww.com/10.1097/HS9.0000000000000586 |
| spellingShingle | Frank W. G. Leebeek New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome HemaSphere |
| title | New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome |
| title_full | New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome |
| title_fullStr | New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome |
| title_full_unstemmed | New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome |
| title_short | New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome |
| title_sort | new developments in diagnosis and management of acquired hemophilia and acquired von willebrand syndrome |
| url | http://journals.lww.com/10.1097/HS9.0000000000000586 |
| work_keys_str_mv | AT frankwgleebeek newdevelopmentsindiagnosisandmanagementofacquiredhemophiliaandacquiredvonwillebrandsyndrome |